New Medicare Pricing Proposal: Ways to Shrink Infusion Drug Costs

Drug costs under Medicare can feel confusing enough when you pick up a prescription at the pharmacy. They can feel even harder to predict when the medicine is given in a hospital outpatient department, infusion center, or clinic. That is why a new federal proposal is drawing attention: Medicare officials say they want to reduce certain hospital markups on discounted outpatient drugs, a change that could lower what some beneficiaries pay over time.

That does not mean every patient will see an immediate bill drop, and it does not mean all infused or injected drugs will suddenly become cheap. The current policy is a proposed rule tied to the hospital outpatient payment system for 2027, not an across-the-board guarantee. Still, the proposal matters because it highlights something consumers can act on right now: where and how a drug is billed can change your out-of-pocket costs.

If you or a family member receives infusion treatments, injections in a clinic, cancer supportive drugs, eye injections, or other medicines administered by a provider, a few careful checks may help you avoid paying more than necessary. The goal is not to self-diagnose billing rules. It is to ask sharper questions before treatment, compare settings when appropriate, and use official Medicare information to estimate what you may owe.

Recent reporting from the Associated Press and the Centers for Medicare & Medicaid Services says the proposal would change reimbursement for certain 340B-acquired outpatient drugs in hospitals, aiming to better match payment to hospitals’ acquisition costs. Consumer cost sharing may fall in some cases if the rule is finalized. Separately, site-neutral payment changes are already affecting some off-campus hospital outpatient settings, which can also matter for coinsurance.

Problem: Why are clinic and hospital drug bills often so hard to predict?

The biggest issue is that the same medication can lead to different costs depending on the setting, the billing pathway, and whether Medicare treats it as a medical benefit or a pharmacy benefit.

Many people assume a drug is a drug: if it is the same medicine, the price to the patient should be similar wherever they receive it. In real life, Medicare billing does not always work that way. A medication given by infusion or injection in a medical setting is often covered under Medicare Part B, while self-administered drugs usually fall under Part D. But some situations are mixed, and supplemental coverage can change what you actually pay.

For Original Medicare, Part B drugs are commonly subject to 20% coinsurance after the deductible, unless you have Medigap or other secondary coverage that picks up some or all of that share. That means the amount Medicare approves for the drug and the administration service matters a lot. A higher approved amount can translate into higher coinsurance. If the provider does not accept assignment, there may also be additional billing exposure in some cases.

What makes this timely is not just the proposed 340B payment cut. It is the broader reminder that hospital outpatient drug pricing rules are still shifting, and beneficiaries can benefit from checking costs before each treatment cycle instead of assuming last year’s pattern still applies.

Hospital outpatient departments have long been a focus in Medicare cost debates because services there can cost more than in a physician office or independent clinic. KFF has explained that site-neutral payment reforms are intended, in part, to bring some payments in certain off-campus hospital settings closer to physician-office rates. That can matter for drug administration services and related beneficiary cost sharing.

There is also the practical issue of timing. Provider contracts, billing practices, annual Medicare payment rules, and Part D plan formularies can change from one year to the next. Even during the same year, where your doctor sends you for treatment may change. A hospital-owned outpatient department might bill differently than a physician office, even when the care feels similar to you as a patient.

In short, a high bill does not automatically mean a mistake was made. But it does mean you should slow down and confirm the basics before the next visit.

Options: What can you check before treatment to possibly lower what you pay?

Start with three comparisons: site of care, Part B versus Part D, and the Medicare-approved amount.

These checks are widely useful because they do not depend on one exact diagnosis. They can help people receiving chemotherapy support drugs, biologics, infusion therapies for autoimmune conditions, osteoporosis injections, ophthalmology drugs, and many other clinic-administered medications.

• Compare the site of care. Ask whether the drug must be given in a hospital outpatient department or whether a physician office, ambulatory infusion suite, or other Medicare-eligible setting could provide the same treatment safely. Your doctor may have valid medical reasons for one setting over another, but it is still worth asking. If there is a clinically appropriate lower-cost setting, your share may be lower.

• Confirm whether the medication is billed under Part B or Part D. This affects not only cost sharing but also which rules apply, which plan tools you can use, and whether prior authorization or formulary restrictions come into play. Call Medicare, your Part D plan, or your Medicare Advantage plan if the classification is unclear. A front-desk estimate is helpful, but your insurer’s explanation is more reliable.

• Ask whether the provider accepts Medicare assignment. If they do, they agree to the Medicare-approved amount as full payment for covered services. That limits what you can be charged to the deductible and coinsurance, if applicable. If they do not, your costs can be less predictable.

• Ask for the Medicare-approved amount before treatment, not just the gross charge. This is one of the most practical questions you can ask. A hospital’s chargemaster price does not tell you what Original Medicare will recognize for payment. The approved amount is a better clue to your likely coinsurance. If you are in a Medicare Advantage plan, ask for the expected member cost share for that exact setting and drug.

• Request a billing estimate that breaks out the drug itself, administration fees, and any facility fee. This helps you compare apples to apples if your doctor offers more than one location.

• If you have Original Medicare plus Medigap, verify how your supplement handles Part B coinsurance for infused or injected drugs. If you have Medicare Advantage, check whether a specific infusion center is in network and whether a hospital outpatient department would cost more.

• Review any notice from your plan or provider about prior authorization, step therapy, or changes in preferred infusion locations. Sometimes a plan will encourage a lower-cost setting, which can be frustrating operationally but cheaper financially.

None of these checks guarantee a lower bill. But they can help you spot whether a cost difference is driven by medical necessity, plan rules, or simply where the claim is being submitted.

It is also worth remembering that the new federal proposal is aimed at a specific issue: hospitals acquiring certain drugs at deep discounts through the 340B program, then receiving a reimbursement formula critics say can produce inflated payments. According to the CMS fact sheet for the proposed 2027 outpatient rule, Medicare would reimburse those 340B-acquired outpatient drugs at ASP minus 33.4% rather than ASP plus 6%. News coverage says officials expect this could reduce beneficiary cost sharing in affected cases.

That matters most as a system-level change, but consumers do not have to wait for final rulemaking to become smarter shoppers within Medicare’s rules. The same core habits help now: compare settings, verify benefit category, and ask for the amount Medicare recognizes.

Next steps: How should you make a treatment-cost decision without delaying care?

Use a short decision path that protects both your health timeline and your wallet.

If the treatment is urgent, you may not have time to investigate every billing angle. But in many recurring-treatment situations, there is enough time to make a few calls before the next appointment. Keep the process simple.

First, call the prescribing doctor’s office and ask three direct questions: What is the exact drug name? Where will it be administered? Is there another clinically appropriate location that bills Medicare differently? If staff mention a hospital-owned infusion site, ask whether they can also price it through a physician office or independent center.

Second, call your coverage source. For Original Medicare, that may mean Medicare and your Medigap carrier. For Medicare Advantage, call the plan’s member services line. Ask whether the drug is treated under Part B or Part D, whether the proposed treatment location is in network, and what your cost share would likely be in alternate settings. Ask the representative to note the call.

A useful rule of thumb: do not rely only on the doctor’s scheduling staff or on an online rumor about a new Medicare drug rule. Confirm the exact billing pathway with Medicare or your plan before assuming your coinsurance will go down.

Third, ask the provider’s billing office for the Medicare-approved amount or a patient estimate based on the planned code set. If they cannot give a final number, ask for their best estimate of the drug charge, administration charge, and any outpatient facility component. Even a rough estimate can reveal whether one site looks materially more expensive.

Fourth, if your bill still looks high after treatment, compare the Medicare Summary Notice or your Explanation of Benefits against what you were told in advance. Look for the place of service, whether assignment was accepted, and whether the claim was processed under the expected part of Medicare. If something appears off, contact the billing office and your plan promptly rather than assuming the amount is fixed.

Finally, keep perspective on what this new proposal does and does not mean. It is real, current, and worth watching. Official CMS materials and major news reporting indicate the agency is trying to reduce excessive reimbursement tied to some discounted hospital-acquired drugs. But until final rules take effect, consumer savings are still partly about old-fashioned preparation: asking better questions, comparing treatment locations, and understanding whether your medicine is moving through Part B or Part D.

For official details, review the CMS outpatient proposed rule fact sheet, the AP report on the proposal, and Medicare’s page on whether a provider accepts Medicare as full payment. If your medication may be covered as a pharmacy benefit, also review your current plan documents or Medicare Plan Finder information for formulary and cost-sharing details.

A few phone calls before your next infusion may feel tedious, but they can be worth it. If you are weighing treatment settings or plan costs, check your current options and pricing details today while the information is fresh.